GT Biopharma, Inc. (GTBP)
NASDAQ: GTBP · Real-Time Price · USD
2.685
-0.016 (-0.61%)
Jun 6, 2025, 2:47 PM - Market open

GT Biopharma Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2015 - 2019
Period Ending
Mar '25 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2015 - 2019
Selling, General & Admin
7.098.577.1112.4547.926.28
Upgrade
Research & Development
6.125.86.478.819.590.49
Upgrade
Operating Expenses
13.2114.3613.5821.2657.526.76
Upgrade
Operating Income
-13.21-14.36-13.58-21.26-57.52-6.76
Upgrade
Interest Expense
---0.21-0.01-0.72-3.32
Upgrade
Interest & Investment Income
0.290.40.780.290.04-
Upgrade
Other Non Operating Income (Expenses)
0.240.84.820.120.21-0.23
Upgrade
EBT Excluding Unusual Items
-12.67-13.16-8.19-20.85-57.98-10.31
Upgrade
Gain (Loss) on Sale of Investments
0-0.05-0.03-0.03-
Upgrade
Legal Settlements
------5.38
Upgrade
Other Unusual Items
1-0.55---12.6
Upgrade
Pretax Income
-11.67-13.16-7.6-20.88-58.01-28.3
Upgrade
Earnings From Continuing Operations
-11.67-13.16-7.6-20.88-58.01-28.3
Upgrade
Net Income
-11.67-13.16-7.6-20.88-58.01-28.3
Upgrade
Net Income to Common
-11.67-13.16-7.6-20.88-58.01-28.3
Upgrade
Shares Outstanding (Basic)
221110
Upgrade
Shares Outstanding (Diluted)
221110
Upgrade
Shares Change (YoY)
50.37%40.78%26.87%13.18%542.06%29.59%
Upgrade
EPS (Basic)
-5.46-6.94-5.64-19.66-61.81-193.58
Upgrade
EPS (Diluted)
-5.46-6.94-5.64-19.66-61.81-193.58
Upgrade
Free Cash Flow
-10.94-12.9-8.85-15.22-15.61-7.26
Upgrade
Free Cash Flow Per Share
-5.12-6.80-6.57-14.32-16.63-49.68
Upgrade
EBITDA
------6.76
Upgrade
D&A For EBITDA
-----0
Upgrade
EBIT
-13.21-14.36-13.58-21.26-57.52-6.76
Upgrade
Updated Feb 21, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q